FIELD: medicine.
SUBSTANCE: present group of inventions refers to medicine, namely to oncology, and concerns the treatment of cancer. For this purpose insert plinabulin in combination with taxane.
EFFECT: combined administration provides the possibility of treating large tumors – more than 3 cm, as well as a decrease in grade 3 or 4 neutropenia, which developed as a result of monotherapy with taxane.
21 cl, 10 tbl, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| NEUTROPENIA REDUCTION METHOD | 2018 |
|
RU2790989C2 |
| METHOD OF TREATING CANCER ASSOCIATED WITH A RAS MUTATION | 2016 |
|
RU2736045C2 |
| COMPOSITION AND METHOD OF REDUCING CHEMOTHERAPY-INDUCED NEUTRPENIA BY ADMINISTRATION OF PLINABULIN AND G-CSF AGENT | 2019 |
|
RU2798103C2 |
| METHOD FOR REDUCING NEUTROPENIA | 2017 |
|
RU2760348C2 |
| COMPOSITION AND METHOD FOR REDUCING THROMBOCYTOPENIA BY INTRODUCING PLINABULIN | 2019 |
|
RU2808652C2 |
| COMBINED CHEMOTHERAPY | 2010 |
|
RU2587013C2 |
| COMBINED CHEMOTHERAPY | 2006 |
|
RU2429838C2 |
| METHOD FOR TREATING A BRAIN TUMOR | 2016 |
|
RU2728796C2 |
| METHODS OF TREATING SOLID TUMORS | 2017 |
|
RU2737934C2 |
| METHOD AND COMPOSITION FOR PERORAL INTAKE OF TAXANES BY A PATIENT | 1998 |
|
RU2205005C2 |
